Doravirine

Drug Profile

Doravirine

Alternative Names: MK-1439; MK-1439-019

Latest Information Update: 27 Mar 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antiretrovirals; Nitriles; Pyridones; Small molecules; Triazoles
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 28 Feb 2017 Merck has patent protection for doravirine in USA (Merck Annual report 2016)
  • 28 Feb 2017 Positive 48-week efficacy data from a phase III trial in HIV-1 infections released by Merck (2016 Merck Annual report)
  • 13 Feb 2017 Adverse events and efficacy data from a phase III trial in HIV-1 infections presented at the 24th Conference on Retroviruses and Opportunistic Infections (CROI-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top